ZAKA VC — 2025 Investments

2 investments dated 2025 · listed companies and verified rows first · show all

Cirrus Therapeuticscirrustx.com inAug 2025

Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy.

BiotechHealthtechLongevityCambridge, US

Ying Kai Chan(Co-founder & CEO)inAndrew Dick(Director, Promoter)

BoardAlexandra Cantley(Director)inKhoo Shih(Director)

Co-investorsClavystBio Long Game Polaris Partners

Nephrogennephrogenbiotech.com inSeed · Nov 2025

Nephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases.

AI & Machine LearningBiotechData & InfrastructureHealthtechMedical DevicesNew York City, US

Demetri Maxim(Founder and CEO)Demetri M.(Founder)inVivek Bhalla(Chief Medical Officer)

Co-investorsChicago Early Growth Ventures (CEGV)Gaingels National Kidney Foundation, Inc.Novogenia GmbH StartX Techstars +14 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.